Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Blood

Volumn 120, Issue 12, 2012, Pages 2466-2474

  Yan, Pearlly ^a   Frankhouser, David ^a   Murphy, Mark ^a   Tam, Hok Hei ^a   Rodriguez, Benjamin ^a   Curfman, John ^a   Trimarchi, Michael ^b   Geyer, Susan ^a   Wu, Yue Zhong ^a   Whitman, Susan P ^a   Metzeler, Klaus ^a   Walker, Alison ^a   Klisovic, Rebecca ^a   Jacob, Samson ^c   Grever, Michael R ^a   Byrd, John C ^a   Bloomfield, Clara D ^a   Garzon, Ramiro ^a   Blum, William ^a   Caligiuri, Michael A ^a   Bundschuh, Ralf ^c   Marcucci, Guido ^a,b   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BINDING PROTEIN; METHYL BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CHROMOSOME; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; FEMALE; GENE SEQUENCE; GENOME; HUMAN; MALE; PRIORITY JOURNAL;

EID: 84866551964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429175     Document Type: Article

References (25)

1. Estey E. AML in older patients: are we making progress? Best Pract Res Clin Haematol. 2009;22(4):529-536.
2. Dombret H. Gene mutation and AML pathogenesis. Blood. 2011;118(20):5366-5367.
3. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:43-50.
4. Plass C, Oakes C, Blum W, Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol. 2008;35:378-387.
5. Kaiser J. Epigenetic drugs take on cancer. Science. 2010;330:576-578.
6. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473-7478.
7. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
8. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.
9. Rodriguez BAT, Frankhouser D, Murphy M, et al. A scalable, flexible workflow for MethylCap-seq data analysis. IEEE Int Workshop Genomic Signal Process Stat. 2011;1-4.
10. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
11. Riethman H, Ambrosini A, Paul S. Human subtelomere structure and variation. Chromosome Res. 2005;13(5):505-515. (Pubitemid 41205633)
12. Brenet F, Moh M, Funk P, et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One. 2011;6(5):e14524.
13. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27.
14. Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26:244-254.
15. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(10):1079-1089.
16. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(21):475-486.
17. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
18. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29(21):1373-1381.
19. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920-6929.
20. Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012;2012:469592.
21. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5):1106-1107.
22. Irizarry RA, Ladd-Acosta C, Wen B, et al. Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue specific CpG island shores. Nat Genet. 2009;41(2):246-250.
23. Qian J, Wang YL, Lin J, et al. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG inland in chronic myeloid leukemia. Eur J Haematol. 2009;82(2):119-123.
24. Blanchette M, Bataille AR, Chen X, et al. Genome-wide computational prediction of transcriptional regulatory modules reveals new insights into human gene expression. Genome Res. 2006;16(5):656-668.
25. Roh T-Y, Cuddapah S, Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev. 2005;19(5):542-552. (Pubitemid 40314987)